We compared the performance of the 19-CNI ‘signature’ to a ‘clinical’ model that included patient age at diagnosis, lymph node status, and tumor size and a ‘clinical + subtype’ model that included clinical covariates combined with tumor subtypes (i.e., LUM A, LUM B, TNBC, and HER2+). This evidence concerns the gene ERBB2 and neoplasm.